For research use only
| Cat No. | ABC-TC3959 |
| Product Type | Immune Cells |
| Cell Type | Mononuclear Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Myelodysplastic Syndrome |
| Storage | Liquid Nitrogen |
Bone Marrow is obtained from adult Myelodysplastic Syndrome patients.
Human Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells (Relapsed/Refractory) are isolated from the bone marrow of donors with relapsed or refractory myelodysplastic syndrome (MDS). They are non-passaged and cryopreserved at primary isolation to preserve soluble components relevant to research use. They display a mixed suspension morphology featuring dysplastic erythroid, myeloid, and megakaryocytic components. Functionally, these cells present in vitro characteristics associated with apoptosis resistance, altered hematopoietic differentiation, and leukemia-related transformation profiles. Flow cytometry identifies aberrant expression of stem/progenitor markers (e.g., CD117). Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | Human Myelodysplastic Syndrome Bone Marrow Mononuclear Cells (Relapsed/Refractory), MDS BM-MNCs (RR), Relapsed MDS Bone Marrow MNCs, Refractory Myelodysplastic BM Cells |
| Species | Human |
| Cat.No | ABC-TC3959 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Myelodysplastic Syndrome |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Immune Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Myelodysplastic Syndrome Bone Marrow Mononuclear Cells (Relapsed/Refractory) serve as an in vitro model for investigating MDS-associated cellular and molecular profiles. By analyzing their acquired genetic mutations (e.g., NRAS, FLT3), dysregulated hematopoiesis, and microenvironmental adaptations, researchers can explore molecular pathways associated with drug resistance and leukemic transformation, supporting discovery research and target identification for MDS-related molecular mechanisms.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).